InSphero is the pioneer of industrial-grade cell dosing solutions and 3D organ-on-a-chip technology without scaffolding. Through partnerships, InSphero helps pharmaceutical and biotechnology researchers make successful decisions by accurately reconstructing human physiology in vitro. Its robust and precisely designed suite of InSight 3D platforms for human™ tissue is used by leading pharmaceutical companies around the world to increase the efficiency of drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (diabetes e.B. T1 and T2 and liver disease NAFLD and NASH) and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura technology that underpins the company`s InSight 3D discovery and™ security platforms includes 96- and 384-well plate formats, as well as the Akura™™ Flow organ-on-a-chip system to drive effective innovation at all stages of drug development. Hiroshi Nakao, Vice President of Yokogawa and head of the company`s life innovation headquarters, said: "As one of our three long-term sustainability goals for 2050, we are working to ensure the well-being of all. Through this partnership, we will be able to offer seamless services ranging from the design of high-quality 3D in vitro models to complex analyses, helping to improve screening technologies and the speed of drug discovery. Yokogawa Electric Corporation (TOKYO: 6841) announces that it has entered into a partnership agreement with InSphero AG, a pioneer in the development of in vitro 3D technologies*1 for drug discovery and safety. The goal of both companies is to establish and further develop methods for the use of high-grade*2 (HCA) analyses in drug discovery and safety assessment. Together, they will promote and support the use of high value-added HCA solutions in drug discovery using in vitro 3D models*1. As part of this partnership agreement, InSphero began using Yokogawa`s confocal CQ1 quantitative image cytometer in its research laboratory. The companies participated in several joint presentations and co-authored a publication in the journal SLAS Discovery that presented a framework for optimizing high-content imaging of 3D models for drug discovery.
Schlieren, Switzerland – December 3, 2020 InSphero AG, the pioneer of cell-based 3D dosing technology, today announced that it has entered into a partnership agreement with Yokogawa Electric Corporation (Tokyo: 6841) to establish and advance high-content imaging and analysis (HCA) in drug discovery and safety. The goal of both companies is to promote and support the use of innovative HCA solutions with in vitro 3D models. The new partnership will focus on establishing and advancing high-grade screening solutions using complex and physiologically relevant 3D cellular disease models. PDF Version Learn more about Yokogawa`s HCA solutions on www.yokogawa.com/solutions/products-platforms/life-science/high-content-analysis Learn more about www.insphero.com. Follow the company on Twitter and LinkedIn. As part of this partnership agreement, InSphero began using Yokogawa`s confocal CQ1 quantitative image cytometer in its ongoing drug discovery and safety programs. In the life sciences journal SLAS Discovery, the two companies jointly published a paper*4 on an optimal HCA method using 3D multicellular spheroid models for drug discovery. InSphero and Yokogawa will be able to leverage deep learning and other HCA capabilities to explore and develop new high-content imaging and analysis solutions for in vitro 3D models. Yokogawa was founded in 1915 and is active in the fields of measurement, control and information.
The industrial automation sector provides key products, services and solutions for a variety of process industries, including petroleum, chemicals, natural gas, energy, iron and steel, and pulp and paper. With the Life Innovation business, the company aims to radically improve productivity throughout the value chains of the pharmaceutical and food industries. Test & Measurement, Aerospace and other companies continue to provide critical instruments and equipment with state-of-the-art accuracy and reliability. Yokogawa partners with its customers through a global network of 114 companies in 62 countries and generated revenue of $3.7 billion in fiscal 2019. For more information, see www.yokogawa.com. Improve efficiency with the CSU-W1 confocal scanner. Media Contacts Dr. Frank Junker InSphero Chief Business Officer Phone +41 44 5150490 [email protected]. Yokogawa`s high-content analysis systems and dual-rotation confocal technologies provide high-speed, high-resolution living cellular imaging, enabling cutting-edge research around the world.
For a wide range of research applications, from basic research to drug discovery screening, Yokogawa`s Life Innovation business offers high-grade analysis (HCA) systems, also known as high-grade screening systems (HCS). Combined with our advanced analysis software, these HCA systems provide high-quality 3D imaging for enhanced analysis of living cells, allowing researchers to identify substances such as small molecules, peptides and RNAi that can alter a cell`s phenotype. High-resolution microscopic images taken with Yokogawa HCA instruments can be used to detect cellular phenotypic changes at the molecular level, making them a powerful tool for studying the effects of physiologically active substances such as siRNA, peptides and antibodies on cultured cells, tissue samples and whole organisms. 120 seconds Introduction to CancerOus Applications of InSpheros 3D InSight Tumor Microtises Yokogawa`s CellVoyager series of high-throughput screening systems™ is equipped with the company`s confocal csu scanner unit, which scans cells at high speed and enables high-resolution 3D imaging for screening candidate compounds. In addition, the deep learning capability of cellPathfinder`s high-content analysis software enables complex image analysis techniques such as phenotypic analysis*3. Together, InSphero and Yokogawa will advance the use of HCA technologies and methods, meeting the growing demand for these solutions in applications such as drug discovery. .